Abel Hall LLC’s Lucid Diagnostics LUCD Stock Holding History

Abel Hall LLC’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,728	Closed	-$29.6K	–	1033
2026 Q1	$29.6K	Sell	25,728 -4,893	-16%	-$6.23K	0.01%	777
2025 Q4	$33.4K	Buy	+30,621	New	+$34.2K	0.01%	677

Other funds holding LUCD

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Abel Hall LLC's LUCD Position: Q2 2026 in Review

Abel Hall LLC sold out of Lucid Diagnostics (LUCD) in Q2 2026, closing a stake of 25,728 shares — an estimated $29.6K sold.

Abel Hall LLC first reported a position in LUCD in Q4 2025 and held it in 2 quarters. The position peaked at $33.4K in Q4 2025. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

Abel Hall LLC reported no remaining Lucid Diagnostics position as of Q2 2026 after selling out during the quarter.
Abel Hall LLC sold 25,728 Lucid Diagnostics shares in Q2 2026, an estimated $29.6K.
Abel Hall LLC first reported a position in Lucid Diagnostics in Q4 2025 and held it in 2 quarters.
Abel Hall LLC's Lucid Diagnostics position peaked at $33.4K in Q4 2025.
116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.